ArriVent BioPharma's (AVBP) "Buy" Rating Reaffirmed at BTIG Research

Key Points

• BTIG Research reaffirmed its “Buy” rating on ArriVent BioPharma and set a $42 price target, implying 33.5% upside from the prior close.
• Analyst sentiment remains broadly positive, with seven Buy ratings, one Hold and one Sell; the consensus rating is “Moderate Buy” with an average price target of $44.83.
• ArriVent reported a quarterly loss of $1.05 per share, missing the $0.99 consensus estimate. Institutional ownership stands at 9.48%, including a new $112.9 million BlackRock stake.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at BTIG Research in a research note issued on Thursday,Benzinga reports. They currently have a $42.00 price target on the stock. BTIG Research's price target indicates a potential upside of 33.50% from the company's previous close.

Other analysts have also recently issued reports about the stock. Truist Financial upped their price target on shares of ArriVent BioPharma from $43.00 to $45.00 and gave the stock a "buy" rating in a research report on Friday, May 29th. Citigroup reissued a "buy" rating on shares of ArriVent BioPharma in a research report on Thursday. Weiss Ratings reissued a "sell (d-)" rating on shares of ArriVent BioPharma in a research report on Friday, July 17th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of ArriVent BioPharma in a research note on Friday, May 22nd. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $44.83.

ArriVent BioPharma Stock Performance

Shares of NASDAQ:AVBP opened at $31.46 on Thursday. The business's fifty day moving average price is $31.87 and its two-hundred day moving average price is $27.77. The stock has a market cap of $1.47 billion, a PE ratio of -9.07 and a beta of 1.36. ArriVent BioPharma has a one year low of $16.65 and a one year high of $35.83.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.06). As a group, equities research analysts predict that ArriVent BioPharma will post -3.9 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ArriVent BioPharma

A number of institutional investors have recently modified their holdings of AVBP. Quantbot Technologies LP bought a new position in ArriVent BioPharma in the second quarter worth about $59,000. E Fund Management Co. Ltd. bought a new position in shares of ArriVent BioPharma during the second quarter valued at approximately $3,798,000. BlackRock Inc. acquired a new stake in shares of ArriVent BioPharma during the 2nd quarter worth approximately $112,919,000. Deutsche Bank AG bought a new stake in shares of ArriVent BioPharma in the 2nd quarter worth approximately $1,361,000. Finally, Persistent Asset Partners Ltd acquired a new position in ArriVent BioPharma during the 2nd quarter valued at approximately $547,000. Institutional investors own 9.48% of the company's stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source